Is Pfizer an Excellent Dividend Stock to Buy? | PFE Stock Analysis
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 17 Sept 2026, 14:45 UTC
- Recorded by Tahlil Plus
- 17 Sept 2026, 16:23 UTC
AI-generated source summary
Pfizer (PFE) has shown volatile revenue and operating margin trends over the past decade, with significant peaks during the pandemic and subsequent declines. The current revenue stands at $63.70 billion (TTM), with a projected decrease in single-digit revenue growth. Operating margins, after peaking around 40%, have normalized to approximately 26.57%. Return on invested capital has also been volatile, fluctuating between negative 5% and positive 25%, currently at 2.86%. The forward P/E ratio is 9.582, indicating a potential discount compared to the broader market. Despite recent underperformance in key metrics, Pfizer's historical performance and the presence of growth opportunities in its pipeline, particularly in weight-loss treatments, suggest a potential for recovery. The intrinsic value per share is calculated at $50.40 based on a discounted cash flow model, contrasting with the current market price of $27.72, implying an upside potential.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.